Aetna to pay $86M in arbitration settlement to HCA Healthcare

One of the nation’s largest health insurers, Aetna, will pay $86 million to HCA Healthcare after a lawsuit stemming from 2015 led to an arbitration trial.

The case related to Aetna’s out-of-network benefit payment and administration practices in Florida for service and care provided to members in Aetna’s individual Public Exchange products from 2014 to 2016. According to Aetna, which is now owned by CVS Health, coverage under Aetna’s individual Public Exchange products in the sunshine state was not available until after Dec. 31, 2016, according to a public filing from CVS Health.

According to HCA, Aetna paid too little for services rendered to HCA hospitals that provided emergency room care to out-of-network patients with insurance purchased on the public exchange under the Affordable Care Act. HCA Healthcare is a Tennessee-based hospital and healthcare facilities operator and is a Fortune 500 company.

Last year, HCA Healthcare was awarded $150 million by the trial arbitrator. Aetna’s appeal brought that down to $86 million on March 28, 2019. CVS Health, which completed its $69 billion merger with Aetna at the end of 2018, indicated the settlement amount in its first quarter earnings report.

The lawsuit was not the only trouble for Aetna lately. The health insurer also recently settled out of court with a patient who sued over coverage denial in California and is facing another lawsuit from a Florida hospital over other claims of coverage denial.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.